Nyxoah’s Genio Wins Prix Galien UK Award, Accelerating U.S. Rollout
NYXH•Nyxoah’s Genio hypoglossal nerve stimulation system for obstructive sleep apnea won the Prix Galien UK 2026 Award for Best Medical Technology, marking a major industry endorsement. The recognition comes as the device expands through NHS and private UK partners following FDA approval and new financing to accelerate U.S. rollout.
1. Award Recognition
Genio was honored with the Prix Galien UK 2026 Award for Best Medical Technology in London, highlighting its innovative leadless, battery-free hypoglossal nerve stimulation therapy for treating obstructive sleep apnea. This accolade underscores Genio’s impact on patient outcomes and its leadership in sleep disorder solutions.
2. U.S. Expansion and Financing
Following FDA approval in August 2025, Nyxoah secured new financing specifically to scale Genio’s commercial rollout across the United States. The funds will support marketing, training of implanting physicians and partnerships aimed at driving adoption among U.S. sleep centers.
3. Clinical Development and Market Adoption
Genio holds a European CE Mark since 2019 and expanded indications after positive BETTER SLEEP study results. Adoption is growing across Europe and other markets, supported by NHS and private healthcare collaborations that aim to broaden access to this therapy.
